Lucid Diagnostics Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LUCD in the last 30 days.
See all $LUCD insider activity →Lucid Diagnostics (LUCD) shares dropped 27% to $0.55 on October 1, 2026, with no clear cause. Analysts remain optimistic, citing reimbursement advancements. The company's P/S ratio is 15.74, below its historical median. Insiders and investment gurus show mixed activity. Lucid operates in medical diagnostics, focusing on GERD-related products.
Lucid Diagnostics Inc. (LUCD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Lucid Diagnostics Advances Multiple EsoGuard ® and EsoCheck ® Payment, Billing and Coding Pathways Medicare Advisory Panel recommends maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a n
Lucid Diagnostics (LUCD) announced progress in payment, billing, and coding for its EsoGuard and EsoCheck products. CMS recommended maintaining EsoGuard's payment basis, AMA approved a new CPT code for EsoCheck, and CDC/NCHS favorably responded to a new ICD-10 code for EsoGuard results. Lucid expects to submit Medicare claims for tests performed at its Texas lab this month.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LUCD (Lucid Diagnostics Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent LUCD coverage spans earnings, market movers and corporate actions.
The unexplained sell‑off creates downside risk as investors may stay cautious.
The regulatory progress could improve reimbursement and drive near‑term revenue growth, supporting the stock.
The coding approvals could increase claim submissions and reimbursements, supporting near‑term revenue growth.
Small-cap earnings miss with modest cash runway; potential upside if Medicare coverage improves.
Positive earnings beat expectations and a new contract could boost near‑term demand for the EsoGuard test.
AlphAI scores every news story that mentions LUCD with an AI model for sentiment and relevance, and aggregates insider trades from Lucid Diagnostics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lucid Diagnostics (LUCD) shares dropped 27% to $0.55 on October 1, 2026, with no clear cause. Analysts remain optimistic, citing reimbursement advancements. The company's P/S ratio is 15.74, below its historical median. Insiders and investment gurus show mixed activity. Lucid operates in medical diagnostics, focusing on GERD-related products.
3 min readLucid Diagnostics Inc. (LUCD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Lucid Diagnostics Advances Multiple EsoGuard ® and EsoCheck ® Payment, Billing and Coding Pathways Medicare Advisory Panel recommends maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a n
2 min readLucid Diagnostics (LUCD) announced progress in payment, billing, and coding for its EsoGuard and EsoCheck products. CMS recommended maintaining EsoGuard's payment basis, AMA approved a new CPT code for EsoCheck, and CDC/NCHS favorably responded to a new ICD-10 code for EsoGuard results. Lucid expects to submit Medicare claims for tests performed at its Texas lab this month.
2 min readLucid Diagnostics reported Q2 2026 revenue of $1.5M, up 17% from the prior quarter. The company performed 2,770 EsoGuard tests, within its target range. Cash reserves remained at $33.4M, with $16.8M raised from a stock offering. GAAP net loss was $14.7M, or $0.08 per share. Management highlighted progress in commercial coverage and Medicare reimbursement efforts, noting a shift to higher-probability revenue sources. The company also secured $22M in convertible debt and reported a 65% claim adjud
3 min readLucid Diagnostics (LUCD) confirmed its first LBM win with Concert, which covers 10M lives. Analyst Mark Massaro maintained a Buy rating and $2.50 price target, citing strong clinical evidence for its EsoGuard test. Q2 revenue grew 27% YoY to $1.5M, with a loss of 8 cents per share. The company awaits CMS coverage for EsoGuard, with management expressing confidence in a positive draft LCD.
2 min readPAVmed Inc. (NASDAQ: PAVM) reported Q2 2026 results for the quarter ended June 30, 2026 and provided business updates across subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health, and Octeris. Lucid recognized $1.5M EsoGuard revenue and processed 2,770 tests, and secured first lab benefit manager coverage. PAVmed cash was $3.8M; GAAP net loss was $5.5M ($0.87/share).
7 min readSimply Wall St reports Lucid Diagnostics (LUCD) shares fell about 2%. The article cites Q2 2026 revenue of about $1.5M, up from $1.163M, but continued net losses and negative EPS. It highlights a high price-to-sales multiple (35.9x), test volume of 2,770 EsoGuard tests, cash of $33.4M, and ongoing reimbursement and adoption concerns.
5 min readNeedham reiterated a Buy rating on Lucid Diagnostics Inc (NASDAQ:LUCD) and set a $3.00 price target, versus about $0.97. The article cites Q2 2026 EsoGuard test volume up 1% to 2,770, revenue of $1.47M vs $1.43M consensus, and a 6-cent-per-share loss. It notes about $33M cash and continued negative free cash flow.
4 min readLucid Diagnostics (NASDAQ: LUCD) reported Q2 2026 revenue of $1.5 million, up 17% QoQ, driven by 2,770 EsoGuard tests. The company said Concert issued its first Laboratory Benefit Manager coverage policy for EsoGuard. Cash was $33.4 million at June 30, with $11.3 million quarterly burn. It awaits a Medicare draft LCD and is progressing with VA.
6 min readLucid Diagnostics reported Q2 2026 revenue of $1.47 million, up 17% sequentially and above the $1.43 million estimate, driven by more EsoGuard insurance claims recognized. EPS was a loss of 6 cents, matching forecasts. The company performed 2,770 EsoGuard tests and reiterated Medicare coverage as the key near-term catalyst; shares fell slightly in premarket.
5 min read
